HPGC Renmintongtai Pharmaceutical Corporation
Shanghai Stock ExchangeTotal Valuation
HPGC Renmintongtai Pharmaceutical Corporation carries a market capitalization of 4.68B, placing it among publicly traded companies globally. Its enterprise value stands at 5.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.68B |
| Enterprise Value | 5.78B |
Share Statistics
HPGC Renmintongtai Pharmaceutical Corporation currently has 579.89M shares outstanding.
| Shares Outstanding | 579.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
HPGC Renmintongtai Pharmaceutical Corporation trades at a trailing price-to-earnings ratio of 60.80. The price-to-sales ratio is 0.75, and the price-to-book ratio stands at 2.00.
| PE Ratio | 60.80 |
| PS Ratio | 0.75 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | 533.81 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, HPGC Renmintongtai Pharmaceutical Corporation trades at an EV/EBITDA multiple of 26.14 and an EV/FCF ratio of 254.31. The EV/Sales ratio of 0.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.14 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.74 |
| EV / EBITDA | 26.14 |
| EV / EBIT | 26.14 |
| EV / FCF | 254.31 |
Financial Position
HPGC Renmintongtai Pharmaceutical Corporation maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.65, indicating elevated leverage, while an interest coverage ratio of 13.10 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.66 |
| Quick Ratio | 0.21 |
| Debt / Equity | 24.65 |
| Debt / EBITDA | 3.42 |
| Interest Coverage | 13.10 |
Financial Efficiency
HPGC Renmintongtai Pharmaceutical Corporation posts a return on equity of 3.36 and a return on invested capital of 3.97.
| Return on Equity (ROE) | 3.36 |
| Return on Assets (ROA) | 1.34 |
| Return on Invested Capital (ROIC) | 3.97 |
| Return on Capital Employed (ROCE) | 2.95 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.17 |
Taxes
Over the trailing twelve months, HPGC Renmintongtai Pharmaceutical Corporation has paid 43.46M in income taxes, reflecting an effective tax rate of 30.91.
| Income Tax | 43.46M |
| Effective Tax Rate | 30.91 |
Stock Price Statistics
HPGC Renmintongtai Pharmaceutical Corporation's stock has gained approximately 8.17694% over the past 52 weeks. The 50-day moving average sits at 8.85, while the 200-day moving average is 10.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | 8.17694% |
| 50-Day Moving Average | 8.85 |
| 200-Day Moving Average | 10.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, HPGC Renmintongtai Pharmaceutical Corporation generated 7.84B in revenue and converted that into 97.17M in net income, yielding earnings per share of 0.17. EBITDA reached 221.06M, while operating income came in at 221.06M.
| Revenue | 7.84B |
| Gross Profit | 659.13M |
| Operating Income | 221.06M |
| Pretax Income | 140.63M |
| Net Income | 97.17M |
| EBITDA | 221.06M |
| EBIT | 221.06M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
HPGC Renmintongtai Pharmaceutical Corporation holds 883.88M in cash and equivalents against 755.18M in total debt, resulting in a net debt position of -177.08M. Total book value stands at 2.96B, with working capital of 2.72B providing operational flexibility.
| Cash & Cash Equivalents | 883.88M |
| Total Debt | 755.18M |
| Net Debt | -177.08M |
| Equity (Book Value) | 2.96B |
| Book Value Per Share | 5.10 |
| Working Capital | 2.72B |
Cash Flow
After subtracting -11.07M in capital expenditures, free cash flow totaled -11.07M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -11.07M |
| Free Cash Flow | -11.07M |
| FCF Per Share | -0.02 |
Margins
HPGC Renmintongtai Pharmaceutical Corporation operates with a gross margin of 8.41, reflecting its pricing power and cost economics. The operating margin of 2.82 and net profit margin of 1.24 provide insight into operational efficiency.
| Gross Margin | 8.41 |
| Operating Margin | 2.82 |
| Pretax Margin | 1.79 |
| Profit Margin | 1.24 |
| EBITDA Margin | 2.82 |
Dividends & Yields
The company's payout ratio of 7.91 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | 7.91 |
| Shareholder Yield | 0.76 |
| FCF Yield | 0.19 |
Stock Splits
HPGC Renmintongtai Pharmaceutical Corporation's most recent stock split took place on June 14, 2011 with a 2:3 split ratio.
| Last Split Date | 6/14/2011 |
| Split Ratio | 2:3 |
Scores
HPGC Renmintongtai Pharmaceutical Corporation posts an Altman Z-Score of 2.90, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.90 |